Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb is the only treatment that safely and effectively treats advanced tumor metastases, independent of tumor type. Clinical translation of anti-PECAM-1 mAb therapy could revolutionize the treatment of this now-refractory clinical entity. Therefore, we propose to perform the following pre-clinical studies required to translate antiPECAM- 1 mAb-based therapy into phase I clinical trials in cancer patients.
NIH Spending Category: Biotechnology; Breast Cancer; Cancer
Project Terms: Antibodies; base; Cachexia; Cancer Patient; CD31 Antigens; Clinical; design; Disseminated Malignant Neoplasm; Dose; Drug Kinetics; Enzyme-Linked Immunosorbent Assay; Frequencies (time pattern); Goals; Half-Life; Human; Intravenous; Knowledge; malignant breast neoplasm; Malignant Neoplasms; Marketing; melanoma; Monoclonal Antibodies; Mus; Neoplasm Metastasis; Patients; Phase; Phase I Clinical Trials; pre-clinical; preclinical study; Refractory; response; Risk; Schedule; Serum; Small Business Innovation Research Grant; Staging; Toxic effect; Translating; Translations; tumor
